share_log

HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $64

HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $64

HC Wainwright & Co.维持对SpringWorks Therapeutics的买入,将目标股价提高至64美元
Benzinga ·  2023/11/28 09:33

HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and raises the price target from $52 to $64.

HC Wainwright & Co. 分析师罗伯特·伯恩斯维持SpringWorks Therapeutics(纳斯达克股票代码:SWTX)的买入,并将目标股价从52美元上调至64美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发